Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | BDKRB1 | P46663 | 16/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4154594 | 0.87 | BDKRB1 (0.44) | BDKRB1 | |
| SCHEMBL5951049 | 0.87 | BDKRB1 (0.44) | BDKRB1 | |
| SCHEMBL4145560 | 0.84 | NPY5R (0.35) | BDKRB1 | |
| SCHEMBL3570792 | 0.79 | MAP3K14 (0.41) | BDKRB1 | |
| SCHEMBL3570796 | 0.79 | MAP3K14 (0.41) | BDKRB1 | |
| SCHEMBL4142908 | 0.77 | NPY5R (0.47) | BDKRB1 | |
| SCHEMBL4148884 | 0.77 | CYP3A4 (0.41) | HTTALDH1A1CYP2D6MEN1KMT2A | |
| SCHEMBL4155517 | 0.75 | ALKBH5 (0.34) | BDKRB1 | |
| SCHEMBL4150330 | 0.74 | HRH3 (0.42) | HTTALDH1A1CYP2D6MEN1KMT2A | |
| SCHEMBL4155448 | 0.74 | HRH3 (0.45) | HTTALDH1A1CYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-7425631-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-20050124654-A1 | Compounds and methods of use | AMGEN INC. | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124654-A1 | Compounds and methods of use | LTC4S, PTGES, LTB4R2 | HTT 1860/4885ALDH1A1 353/4885CYP2D6 48/4885 |
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | LTC4S, PTGES, LTB4R2 | HTT 1860/4885ALDH1A1 353/4885CYP2D6 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.